REGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp lifted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 13.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 149,280 shares of the biotechnology company’s stock after buying an additional 17,563 shares during the quarter. Stifel Financial Corp’s holdings in REGENXBIO were worth $1,566,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of RGNX. Redmile Group LLC boosted its stake in REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock worth $51,327,000 after buying an additional 323,100 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of REGENXBIO in the 3rd quarter worth about $140,000. Verition Fund Management LLC purchased a new stake in shares of REGENXBIO during the 3rd quarter worth about $432,000. BNP Paribas Financial Markets lifted its position in REGENXBIO by 602.9% during the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 17,533 shares in the last quarter. Finally, FMR LLC increased its position in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,656 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on RGNX shares. Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. HC Wainwright lowered their target price on REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Morgan Stanley reissued an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of REGENXBIO in a research report on Wednesday, December 11th. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.27.

Insider Activity at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the transaction, the director now owns 11,286 shares in the company, valued at $114,101.46. This represents a 46.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 13.13% of the stock is owned by insiders.

REGENXBIO Trading Up 2.8 %

RGNX opened at $7.62 on Friday. The business’s 50 day moving average is $9.58 and its 200-day moving average is $11.19. The stock has a market cap of $377.53 million, a PE ratio of -1.51 and a beta of 1.24. REGENXBIO Inc. has a twelve month low of $7.21 and a twelve month high of $28.80.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.